CryoSphere+ leverages new insulation technology, reducing freeze times by 25% compared to the legacy CryoSphere device. The original CryoIce device first received FDA clearance in November 2018 and aided in more than 60,000 procedures to date.
The CryoSphere+ device picked up FDA clearance for temporarily blocking pain by ablating peripheral nerves in adult patients, and by ablating intercostal nerves under direct visualization in adolescent patients (12-21 years of age). Its unique freezing method blocks nerves from transmitting pain signals for several months. The system could offer utility in multi-modal pain management strategies for post-surgery patients.
The new technology in CryoSphere+ minimizes thermal loss by focusing energy at the ball tip. This provides a faster time to therapeutic temperature and reduces freeze time by 25%, in turn reducing operative time.
AtriCure began an extended, limited U.S. launch and expects a full rollout by the end of the second quarter.
“CryoSphere+ is a meaningful innovation that I believe will improve patient care, enhance outcomes, and enable physicians to perform procedures with greater ease and confidence,” said Michael Carrel, president and CEO at AtriCure. “Since the launch of our pain management franchise over five years ago, we’ve seen a significant impact on patient’s lives, and with this launch, we look forward to serving even more people in the future.”
